Bristol’s Termination Of Dolan Follows Federal Monitor’s Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
However, the company’s monitor and the U.S. Attorney for New Jersey conclude that Bristol has not violated a deferred prosecution agreement.
You may also be interested in...
Plavix Takes A Final Bow, But Will It Go Gracefully?
Generic versions of Bristol-Myers Squibb/Sanofi’s blockbuster clot-buster clopidogrel launched in the U.S. May 17, but the companies are helping some patients continue on the brand by covering the high out-of-pocket costs. Following Pfizer’s success retaining share of Lipitor, industry is paying close attention to brand retention programs.
Bristol Pleads Guilty To Criminal Charges To Settle DoJ Investigation Over Plavix
Bristol will pay $1 million to close an investigation related to the renegotiation of a generic settlement with Apotex over Plavix.
Bristol Pleads Guilty To Criminal Charges To Settle DoJ Investigation Over Plavix
Bristol will pay $1 million to close an investigation related to the renegotiation of a generic settlement with Apotex over Plavix.